Dr. Reddy’s Faces GST Penalty Orders for FY 2019–22, Sees No Material Impact
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dr Reddy’s Laboratories ( (RDY) ) just unveiled an update.
Dr. Reddy’s Laboratories disclosed that it has received three orders from the GST Authority’s Commercial Taxes Department, Office of the Joint Commissioner (ST), Chennai Intelligence-II. The orders, issued and received on March 16, 2026, relate to tax demands, including interest and penalties, under Section 74 of the Tamil Nadu Goods and Services Tax Act for financial years 2019-20 to 2021-22.
The authority’s position is that certain supplies made by the company during those years are taxable, leading to penalties of ₹2,19,48,944 for FY 2019-20, ₹50,406 for FY 2020-21, and ₹4,384 for FY 2021-22. Dr. Reddy’s has stated that, based on its evaluation, the orders do not have a material impact on its financials, operations, or other activities, and it will consider filing an appeal with the appellate authority, signaling a likely legal challenge while assuring stakeholders about limited financial exposure.
The most recent analyst rating on (RDY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based global pharmaceutical company focused on developing, manufacturing, and marketing generic medicines, active pharmaceutical ingredients, and proprietary products. It serves regulated markets including India, the U.S., and Europe, and is listed on the NSE, BSE, NYSE, and NSE IFSC, reflecting a diversified international investor base.
With a broad portfolio across therapeutic areas, the company operates in a highly regulated environment where compliance with tax, trade, and healthcare laws is critical. Its scale and geographic spread expose it to periodic regulatory reviews and disputes, including indirect tax assessments in various Indian states.
Average Trading Volume: 1,772,543
Technical Sentiment Signal: Buy
Current Market Cap: $11.52B
For detailed information about RDY stock, go to TipRanks’ Stock Analysis page.
